Close Menu

NEW YORK – In Adaptive Biotechnologies' first ever quarterly results conference call, officials unveiled plans for new products and regulatory approvals.

The Seattle-based immune sequencing firm is developing new research and clinical assays — including a new research-use-only kit and a blood-based diagnostic test dubbed "immunoSeq Dx" — and is pursuing additional regulatory approvals for its existing clinical test, clonoSeq.

Adaptive officials also painted a promising picture of payor coverage for clonoSeq.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.